Clinical efficacy of Doppler-echocardiographic indices of aortic valve stenosis:a comparative test-based analysis of outcome  by Bermejo, Javier et al.
Clinical Efficacy of Doppler-Echocardiographic
Indices of Aortic Valve Stenosis:
A Comparative Test-Based Analysis of Outcome
Javier Bermejo, MD, Rodolfo Odreman, MD, Josefina Feijoo, MD, M. Mar Moreno, MD,
Paz Go´mez-Moreno, RDCS, Miguel A. Garcı´a-Ferna´ndez, MD
Madrid, Spain
OBJECTIVES This study was designed to assess which hemodynamic index best accounts for clinical severity
of aortic stenosis (AS) and to analyze the value of low-dose dobutamine testing.
BACKGROUND Pressure gradient and valve area are suboptimal because they depend on flow rate, correlate
poorly with symptoms, and provide limited prognostic information. Recently, new indices
and low-dose inotropic stimulation have been introduced, but their clinical value remains
uncertain.
METHODS A total of 307 consecutive patients with AS were included in an ambispective study design
(71 12 years old; peak jet velocity: 3.7 1.1 m/s). Clinical and Doppler-echocardiographic
data were obtained, as well as results of low-dose dobutamine infusion (47 patients). Using
receiver-operator-characteristic curve analysis, we evaluated jet velocity, pressure gradient,
valve area, resistance, stroke-work loss (SWL), and dobutamine-induced increase in area for
predicting 1) symptomatic status at entry, 2) early (3 months) cardiovascular death or aortic
valve replacement, and 3) long-term outcome. Logistic regression and Cox models were
designed multivariate and adjusted by bootstrapping.
RESULTS Only 28% of patients were alive without valve replacement at the end of the follow-up period
(22  4 months). The decision for valve replacement was made by the referring physician,
blinded to the SWL, valve resistance, and dobutamine results. Non–flow-corrected indices
performed better than valve area and valve resistance. Among them, SWL best predicted the
defined end points. Odds/hazard ratios associated with a SWL   17% were 5.14 for
presenting AS symptoms, 4.68 for early events, and 2.31 for late outcome. A cutoff value of
SWL 25% best discriminated clinical end points. Other independent predictors of
prognosis were symptomatic status and left ventricular ejection fraction. Dobutamine testing
added no value to baseline models.
CONCLUSIONS Non–flow-corrected indices show the highest clinical efficacy in aortic stenosis. Among these,
SWL best predicts symptomatic status and outcome and therefore should be incorporated to
aid patient management in unclear situations. (J Am Coll Cardiol 2003;41:142–51) © 2003
by the American College of Cardiology Foundation
Therapeutic decisions in adult aortic stenosis (AS) are based
on the definition of symptomatic status and of hemody-
namic severity (1). Accurate evaluation of these two issues is
mandatory, because prognosis of asymptomatic patients is
not improved by surgery (2) and because poor outcome
follows replacement of nonseverely stenotic valves (3,4).
However, establishing symptomatic status and severity of
AS is not always straightforward. Assessment of subjective
symptoms and functional capacity is frequently ambiguous,
particularly in the elderly (5). Also, establishing disease
significance can be challenging because a gold standard of
valve obstruction is unavailable (6). Current hemodynamic
assessment of severity relies on indices such as transvalvular
pressure gradient (P) and aortic valve area (AVA) that are
obtained by cardiac catheterization or, more frequently
today, by Doppler echocardiography (1). It is recognized
that these indices are suboptimal because they correlate
poorly with patients’ symptoms (7), provide little prognostic
information (8), and depend on flow rate (9–11). Further-
more, the appropriate cutoff values of AVA and P for
establishing severity are unclear (12). On the basis of
different fluid-dynamic assumptions, aortic valve resistance
(AVR) and left ventricular (LV) stroke-work loss (SWL)
have been proposed as alternative indices of AS (13–15), but
their clinical value remains to be ascertained. Also, it has
been suggested that stress echocardiography may play a
prognostic role in AS (16); by unmasking the reserve of
valve orifice enlargement available when cardiac output
increases, stress echocardiography may predict patients’
symptoms and anticipate valve replacement (16).
Evaluation of diagnostic tests should be performed with a
hierarchical framework in which clinical outcome efficacy
represents the final objective of diagnostic imaging (17–19).
Clinical outcome efficacy summarizes correlation with
symptom severity, functional outcome, patient utility assess-
ment, quality of life, morbidity avoided, and mortality rate
(17,19). Previous longitudinal studies have aimed to identify
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natural-history predictors among classic indices of AS and
have focused on selected patient groups such as asymptom-
atic (2,20–25) or moderate disease (26). Hence, a test-based
comparative evaluation including conventional and alterna-
tive indices is lacking. The present study was designed to
compare the clinical outcome efficacy of severity indices and
of low-dose inotropic stress testing, in terms of 1) symptom
correlation, 2) identification of critical disease, and 3)
prediction of long-term prognosis.
METHODS
Study population. Two patient cohorts constitute the basis
for this study. Forty-seven patients (15%) were prospectively
enrolled on the basis of the following criteria: a diagnosis of
valvular AS, a suitable echocardiographic window, New
York Heart Association functional class I to III, absence of
ventricular arrhythmias, and willingness to participate.
Some of these patients have been the basis of a previous
report (10), and the clinical efficacy of dobutamine testing
was assessed in this cohort. A total of 275 patients were
retrospectively recruited among all inpatients referred for a
Doppler-echocardiographic examination from 4/97 to 4/98
in whom AS was diagnosed. Patients with any 2
valvular regurgitation or more than mild mitral stenosis
were excluded. Follow-up data were unavailable for 15
patients in the retrospective group; no patient from the
prospective cohort was lost. The combination of the pro-
spective and retrospective cohorts constitutes the basis for
this report (Group A, n 307). Group B was derived as the
subgroup of Group A in whom all indices of AS were
available (n  154). Group B was used for selecting the
models with best predictivity among different indices of AS
(model building). The performance of these models was
then measured in Group A (model testing and validation).
The study was approved by the institutional review board
and written informed consent was obtained from all patients
in the prospective cohort; informed consent was obtained
from the patients of the retrospective cohort at the time of
follow-up interview. Clinical characteristics of the study
population are summarized in Table 1.
Clinical data. In the prospective cohort, a full clinical
interview was performed at entry. Patients were carefully
screened for the presence of dyspnea, angina, or syncope
using New York Heart Association functional classification.
Patients manifesting angina, syncope, congestive heart fail-
ure, or exercise dyspnea class 2 were classified as present-
ing symptoms attributable to AS. Comorbidity was assessed
by patient anamnesis followed by careful review of medical
records, and was coded using a well-validated score (27).
Identical criteria were used for collecting clinical data in the
retrospective cohort. Blood pressure was measured at the
time of the echocardiographic examination in the prospec-
tive cohort and taken from the patient’s clinical record
Abbreviations and Acronyms
AS  aortic valve stenosis
AVA  aortic valve area
AVR  aortic valve resistance
CI  confidence interval
EF  ejection fraction
LV  left ventricular
ROC  receiver-operator characteristic
SBP  systolic blood pressure
SWL  stroke-work loss
Vmax  peak transaortic jet velocity
P  mean transvalvular systolic pressure gradient
Table 1. Clinical and Echocardiographic Data of the
Study Populations
Variable
Group A
(n  307)
Group B
(n  154)
Clinical
Age (yrs) 71  12 71  12
Gender [n (%)]
Female 174 (57) 87 (56)
Rhythm [n (%)]
Sinus 215 (70) 97 (63)
Atrial fibrillation 74 (24) 46 (30)
Pacemaker/other 18 (6) 11 (7)
Blood pressure (mm Hg)
Diastolic 70  13 70  15
Systolic 129  21 127  22
Comorbidity index [n (%)]
0 104 (34) 61 (40)
1 89 (29) 48 (31)
2–3 71 (23) 28 (18)
3 43 (14) 17 (11)
Arterial hypertension [n (%)] 138 (45) 75 (49)
Coronary artery disease [n (%)] 67 (22) 32 (21)
AS symptoms [n (%)]
None 90 (29) 30 (19)
Angina 101 (33) 44 (29)
Exertional dyspnea 193 (63) 94 (61)
Syncope 9 (3) 9 (6)
CHF 43 (14) 28 (18)
NYHA functional class [n (%)]
I 80 (26) 30 (19)
II 129 (42) 71 (46)
III–IV 98 (32) 53 (34)
Echocardiographic
LV ejection fraction 0.49  0.23* 0.56  0.14
Aortic regurgitation [n (%)]
0 or 1/4 177 (58) 97 (63)
2/4 128 (42) 55 (36)
3/4 2 (1) 2 (1)
Diastolic mitral inflow profile [n (%)]†
Normal 122 (57) 58 (60)
Delayed relaxation 86 (40) 35 (36)
Restrictive 7 (3) 4 (4)
Aortic stenosis severity
AS jet peak velocity (ms1) 3.7  1.1* 4.2  1.0
Mean pressure gradient (mm Hg) 37  23* 48  20
LV stroke-work loss (%) 21  11* 27  9
Aortic valve area (cm2) 0.6  0.3
Aortic valve resistance (dynesscm5) 354  194
Data presented as mean  SD. *p  0.05 for differences between Groups A and B.
†Only from patients in sinus rhythm.
AS  aortic stenosis; CHF  congestive heart failure; LV  left ventricular;
NYHA  New York Heart Association.
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within a 5-h interval from the index exam in the retro-
spective group. An ad hoc study performed in our laboratory
(40 consecutive inpatients) demonstrated limits of agree-
ment between values of systolic blood pressure (SBP)
measured in the laboratory and values written in the clinical
records in the hospitalization wards to be 4 to 11 mm
Hg (95% confidence interval [CI]).
Doppler-echocardiographic examination. Examinations
were performed using phase-array ultrasound devices (Acu-
son Sequoia [Mountain View, California] or Hewlett-
Packard [Andover, Massachusetts] Sonos 1500 and 2500)
with 2.5/2.0 MHz duplex and 1.9 MHz (Pedoff) transduc-
ers. All exams were either performed (prospective cohort) or
reviewed by one of the investigators. Images and spectro-
grams were obtained from parasternal, apical, subcostal, and
suprasternal views. Left ventricular volumes and ejection
fraction (EF) were measured as recommended (28). Aortic
and mitral regurgitation were graded on the basis of color
flow imaging. Mitral valve area was calculated using two-
dimensional planimetry and the pressure half-time method.
In patients in sinus rhythm, LV diastolic function was coded
according to transmitral pulsed-wave Doppler spectrograms
as 1) restrictive, if the E/A ratio was 2 or E/A ratio was
between 1 and 2 and E-wave deceleration time was 140
ms (29); 2) prolonged relaxation, if the E/A ratio was less
than the 95% CIs of normal age-matched subjects or the
deceleration time was above 95% CI limits (30); and 3)
normal, if neither restrictive or prolonged relaxation criteria
were met.
In the retrospective cohort, measurements of outflow
tract diameter and pulsed-wave spectrogram required to
calculate AVA were performed when peak jet velocity was
3 m/s or LV function was abnormal. This represents
current clinical practice in our laboratory and follows cost-
efficacy recommendations (31). Patients in whom outflow
tract diameter and spectrograms were not recorded were
included in Group A but not in Group B. Measurements
were averaged from 4 to 6 beats of patients in sinus rhythm
and from 6 to 10 consecutive beats in patients in atrial
fibrillation. Valve area and P were calculated using the
continuity and Bernoulli equations, respectively. Valve re-
sistance was calculated as 28  P/AVA (10). Left ven-
tricular SWL was expressed as percentage and obtained as
100  P/P  SPB	 (9,15). Reproducibility values of
indices of AS in our laboratory have been reported (10).
In the prospective group, a low-dose dobutamine infusion
protocol was begun after the baseline study at 5 g/kg body
weight/min up to 20 g/kg/min, titrated upwards at steps of
5 g/kg/min every 5 min (10). Doppler spectrograms of LV
outflow tract and AS jet velocity were obtained within the
last 2 min of each dose. Blood pressure was monitored using
automatic sphygnomanometry. All concomitant vasodilator
and beta-blocker therapy was suspended 24 h before the
index examination. Dobutamine-induced aortic orifice en-
largement was calculated as the absolute difference between
values of AVA observed at peak flow rate and at baseline.
Patient outcome and definition of end points. Clinical
and Doppler echocardiogram patient follow-up was per-
formed on a yearly basis in the prospective cohort. At the
end of the four-year follow-up period, medical charts from
the whole study group were reviewed and patients alive were
directly interviewed. The composite outcome end point was
defined as cardiac death or aortic valve replacement during
the follow-up period. Death was classified as either cardiac
or noncardiac according to patient medical records, infor-
mation provided by the referring physician, and autopsy
data when available. Identical criteria were used in the
retrospective cohort. Aortic stenosis was defined in clinical
terms as critical when the patient’s aortic orifice was small
enough to cause symptoms and require valve replacement or
induce cardiac death during the three months following
patient enrollment. This three-month criterion was estab-
lished at the time of study design because it is the maximum
time recommended for valve replacement for patients who
develop symptoms (25); also, three months is above the time
for performing valve replacement once indicated at our
institution. The decision to indicate valve surgery was made
by the patient’s physician, according to his own interpreta-
tion of symptomatic status. Valve area and P were reported
to the referring physician, whereas AVR, SWL, and the
response to dobutamine were withheld. Patients dying from
noncardiac causes were censored at the date of death, and
patients still alive without valve replacement were censored
at the end of the follow-up period.
Statistical analysis. Variables are described as mean SD.
Association among hemodynamic indices was assessed by
cluster analysis based on Spearman’s correlation coefficient.
All predictive models were designed multivariate. Logistic
regression models were used to assess symptom correlation
and identification of critical AS, whereas long-term out-
come was analyzed by Cox proportional-hazards survival
analysis. Five AS indices (peak transaortic jet velocity
[Vmax], P, AVA, AVR, and SWL) as well as
dobutamine-induced increase in AVA were compared. For
covariable testing, a composite severity score was computed
as the first term of the principal components analysis based
on the correlation matrix of all indices. This score therefore
synthesizes average prediction capability of the five indices,
providing equal weight to each of them. Factors previously
reported to correlate with disease symptoms or outcome
(age, comorbidity, rhythm, symptomatic status, functional
class, LV mass, volumes, diastolic profile, and EF) were
tested as covariables and entered in full saturated models for
each prediction, including only the composite score as index
of severity. Then, relevant covariables were selected by
backward stepwise variable selection based on Alkaike’s
information criterion (32). Next, each severity index was
consecutively substituted in place of the composite severity
score. Finally, dobutamine-induced increase in AVA was
forced in the model of the index showing best baseline
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prediction (prospective cohort). Models were validated by
resampling 400 bootstrap replications to exclude overfit-
ting. Agreement between each dataset (training sample)
and the original data (test sample) was excellent (slope
shrinkage factor 0.9; maximum absolute error in pre-
dicted probability 0.02) (32). Efficacy was compared
computing bias-corrected and adjusted areas under the
receiver-operator characteristic (ROC) curves for models
containing each of the severity indices (33). Using these
models in Group A, cutoff values were obtained using
classification-and-regression trees (34), followed by the
log-rank test when appropriate. All analyses were per-
formed using S-Plus software (MathSoft, version 2000),
expanded by public-domain libraries “survcart” (35), and
“design” and “hmisc” (32,36). Statistical significance was
assumed at p  0.05.
RESULTS
Correlation among hemodynamic indices. Figure 1
shows the association among the five indices of severity.
Non–flow-corrected indices (Vmax, P, and SWL) corre-
lated closely into a single cluster, whereas flow-corrected
indices (AVA and AVR) were grouped in another one.
Correlation between these two clusters was fair (rho 
0.37).
Patient outcome. The follow-up period was 14  16
months (range 10 days to 55 months, median 6 months).
For patients without early events, the follow-up period was
22  14 (median 21) months. Outcome of Groups A and B
is summarized in Figure 2. There were fewer symptomatic
and critical AS patients in Group A than in Group B (71%
vs. 81%, p  0.02; and 39% vs. 55%, p  0.002, respec-
tively). A very high event rate was observed in the study
population, resulting in the fact that only 28% were alive
without valve replacement at the end of the follow-up
period. Probability for performing valve replacement in
symptomatic patients was related (multivariate logistic re-
gression) to younger age (95% CI odds ratio [OR] for  14
years: 0.15 to 0.47; p  0.0001), higher P (95% CI OR 
34 mm Hg: 3.70 to 13.6; p  0.0001), and less comorbidity
(95% CI OR  2 score points: 0.34 to 0.85; p  0.007).
The ROC analysis of clinical efficacy end points is shown
in Figure 3, best unadjusted cutoff values for hemodynamic
indices to predict outcome are summarized in Table 2, and
the results of multivariate prediction models are shown in
Table 3.
Prediction of symptomatic status. No covariables were
retained in the models of symptomatic status prediction.
Box plots of severity indices according to symptomatic
status demonstrated significant overlap of values of AVA
Figure 1. Association among hemodynamic indices of aortic stenosis.
Results of the cluster analysis of variables in Group B show an initial split
into two groups, flow-corrected and non–flow-corrected indices, with a fair
correlation between them (rho2  0.37). Stroke work loss closely correlates
with P, as expected from its calculation formula. Also, there was a close
association between AVA and AVR.
Figure 2. Follow-up data of the study population. Values are shown for patients in Group A and Group B, separated by a slash. AS  aortic valve
stenosis.
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and AVR between symptomatic and asymptomatic patients;
among non–flow-corrected indices, the discriminative
power of SWL was highest (Figs. 3 and 4). Sensitivity,
specificity, and positive and negative predictive values (95%
CI) for the SWL criterion of 23% vs. 23% were 0.54
(0.48 to 0.59), 0.81 (0.74 to 0.87), 0.89 (0.83 to 0.93), and
0.42 (0.36 to 0.48), respectively. The dobutamine test did
not increase predictive accuracy to the model based on SWL
in the prospective cohort (Wald chi-squared  1.30; p 
0.2; area under the ROC curve  0.80 vs. 0.80 with and
without dobutamine increase in AVA).
Identification of critical aortic stenosis (early cardiac
events). Other than AS severity, symptomatic status and
EF at enrollment were identified as independent covariables
related to critical disease. Non–flow-corrected indices of AS
performed better than AVA and AVR and, among them,
SWL was the index showing highest area under the ROC
curve (Fig. 3); also in the validation group, SWL showed
the best predictive accuracy. Figure 5A illustrates the
regression tree for predicting a critical AS in Group A.
Entering dobutamine test information added no prognostic
information to the previous model in the prospective cohort
Figure 3. Clinical efficacy of aortic stenosis indices. Prediction capability is shown for the clinical objectives of predicting: 1) symptomatic status, 2) critical
aortic stenosis (AS), 3) late AS events, 4) early or late AS events in patients with depressed left ventricular function, and 5) any-cause mortality in unoperated
patients. Clinical efficacy is assessed by receiver-operator characteristic analysis for populations derived from Group B (see methods section). EF  ejection
fraction.
Table 2. Unadjusted Best Cut-Off Values of AS Indices to Predict Clinical Outcome
Efficacy End Points
Index
Study Group
Vmax
(m/s)
P
(mm Hg)
SWL
(%)
AVA
(cm2)
AVR
(dynes/s/cm5)
A B A B A B B B
Clinical efficacy objective
AS symptoms 3.4 3.2 29 27 17 23 1.1 125
Late AS events 4.1 4.1 46 46 25 26 0.8 486
Critical AS 3.4 3.7 30 41 26 26 0.7 228
Average 3.6 3.7 35 38 23 25 0.9 280
AS  aortic valve stenosis; AVA  aortic valve area; AVR  aortic valve resistance; P  mean transvalvular pressure gradient;
SWL  LV percentage stroke work loss; Vmax  peak transaortic jet velocity.
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(Wald chi-squared  0.97, p  0.35; area under the ROC
curve: 0.94 vs. 0.95 for models with and without the
dobutamine effect, respectively).
Prediction of long-term outcome. Outcome of patients in
Group B was slightly worse than of patients in Group A.
Figure 6 shows unadjusted long-term survival plots accord-
ing to each index of severity in group B. For the analysis of
long-term outcome efficacy, patients with critical AS were
excluded. Best stratification was observed for non–flow-
corrected indices, and again, SWL was best (Figs. 3 and 6).
Survival without AS events was almost identical for groups
with AVA  0.75 cm2 and patients with AS in the 0.75 to
1 cm2 range. The only independent predictor other than AS
severity in the Cox model analysis of long-term outcome
was symptomatic status at entry. Outcome of all patients
with SWL25% was very poor, and95% of symptomatic
patients with SWL above this value had suffered cardiac
death or had undergone valve replacement by three years
(Fig. 5B). In the prospective cohort, dobutamine added no
relevant information to SWL and symptomatic status
(Wald chi-squared  2.16, p  0.15; area under the ROC
curve  0.79 vs. 0.78 for the models with and without
dobutamine information, respectively).
Patients with abnormal systolic function. Twenty-nine
patients in Group B (19%) and 48 patients in Group A
(16%) had LV systolic dysfunction (EF  0.45). In Group
B, 27 of these patients had AS events: 14 cardiac deaths and
13 aortic valve replacements. Multivariate outcome analysis
ruled out prognostic significance of the symptomatic status
and EF in this group of patients. Again, SWL was the index
showing highest area under the ROC curves. All patients
with SWL 25% and EF 0.45 had had an AS event in
less than one year (Fig. 5C), irrespective of their symptom-
atic status.
Overall mortality of patients that did not undergo sur-
gery. There were 60 and 176 patients not operated on in
Groups B and A, respectively, 36 (64%) and 91 (52%) of
whom died during follow-up, respectively. Clinical efficacy
to predict overall mortality was again maximal for SWL
(Fig. 3). Variables included in the proportional-hazards
model for assessing the risk of cardiac death were SWL
(95% CI HR 13%: 1.13 to 1.92), comorbidity (95% CI
HR 2 points: 1.02 to 1.26), age (95% CI HR 14 years:
1.35 to 2.52), presence of AS symptoms (95% CI HR 
1.09 to 2.68) and EF (95% CI HR 15% 0.52 to 0.86).
The superiority of non–flow-corrected indices over AVA
and AVR was corroborated in patients in sinus rhythm for
the three major efficacy end points.
DISCUSSION
Onset of dyspnea, angina, or syncope identifies a critical
point in the natural history of AS (37). Once symptoms
appear, average survival rapidly falls and prompt valve
replacement is warranted. Because the risk of sudden death
while patients remain asymptomatic does not outweigh the
complications of artificial prostheses, valve replacement
should be withheld until patients become symptomatic (1).
Although they are well established, it is recognized that
these guidelines are based on retrospective studies that
defined the spontaneous course of mostly congenital and
rheumatic disease (20,22,37,38). Today’s clinical spectrum
of AS is different. Calcific-degenerative has become the
most frequent etiology, and AS is now a highly prevalent
disease in the elderly (39,40). These changes are frequently
responsible for uncertainty regarding the definition of op-
timal timing of valve replacement in individual patients.
First, defining symptomatic status is particularly difficult in
the elderly (5). Second, whether mild exertion dyspnea
should be considered an index symptom in order to recom-
mend surgery also remains controversial (25). Third, degen-
erative AS is known to be related to widespread cardiovas-
cular involvement (41), and even when symptoms are clear,
it may be impossible to discern whether they are related to
the disease or to associated ischemic or hypertensive cardio-
myopathy. Finally, concomitant obstructive lung disease, a
common disease in the elderly, may account for patients’
dyspnea instead of AS (5).
A robust measurement of disease severity is mandatory in
these contexts. It is recognized that clinical outcome is the
only end point available for defining severity, owing to the
lack of any hemodynamic gold standard (2). This is the first
study to compare clinical efficacy of different indices of AS
and demonstrates the superiority of non–flow-corrected
indices in a broad population. Multiple theoretical and
technical studies have demonstrated that AVA is the index
that best characterizes the severity of the outflow obstruc-
tion caused by a stenotic valve (42,43). However, best
technical efficacy does not necessarily imply superior clinical
outcome efficacy (18). Although they are limited to mea-
suring AS severity from a fluid-dynamic viewpoint, non–
flow-corrected indices account for additional factors such as
LV and systemic response to the outflow obstruction.
Among non–flow-corrected indices, SWL showed high-
est clinical efficacy, even in patients with impaired LV
function. The present study demonstrates that if SWL is
Table 3. Multivariate Clinical Efficacy Prediction Models in
Group A (n  307)
Prediction Model/Variables
Odds/Hazards
Ratio
95%
Confidence
Interval
Symptomatic status
SWL  17% 5.14 3.02–8.77
Critical AS
AS symptoms 6.85 3.02–15.54
SWL  17% 4.68 2.83–7.73
LV ejection fraction  0.20 0.88 0.69–1.12
Late AS events
SWL  17% 2.31 1.58–3.37
AS symptoms 2.13 1.30–3.49
Odds and hazard ratios are shown for logistic and proportional hazard models,
respectively. Models selected in Group B patients.
  increment in quantitative independent variables. Abbreviations as in Table 2.
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23%, probability of showing symptoms attributable to AS
is 80% at the time of the echo-Doppler exam; if SWL is
25%, median cardiac survival without valve replacement is
close to one year, or slightly better the patient is asymptom-
atic; and if SWL is 26% probability of events is 30% in
the following three months, increasing to 87% if the patient
is symptomatic. Although it may be argued that valve
replacement is a “soft” end point that is arbitrarily deter-
mined during the natural history of the disease, it is
noteworthy that referring physicians based their decision to
operate on AVA and P, unaware of the values of SWL.
Furthermore, 67 out of 198 AS events (34%) were cardiac
deaths, thereby allowing assessment of the natural history of
the disease in a relatively large number of patients.
Although SWL was proposed more than 30 years ago
(15), little attention has been paid to its clinical application.
From a fluid-dynamic basis, this index represents the
amount of energy the LV dissipates as heat because of
outflow obstruction (15,44). Invasive studies have demon-
strated an inverse and quadratic correlation between SWL
and AVA, and values 30% predict a critically narrow
orifice (44); this value is close to the cutoff values identified
in the present study. A number of reasons may account for
the highest outcome efficacy of this index. According to its
formula, SWL can be interpreted as a blood-pressure
normalization of P. Low systolic blood pressure is a
hallmark of severe AS (45), and SWL accounts for such
effect: higher values are obtained as blood pressure falls for
a given P. Blood pressure response to AS is known to be
subject to a number of factors, particularly age. Therefore
the findings of our study, demonstrating maximal prognos-
tic value of SWL in a cohort with a majority of elderly
patients, justify further investigation on peripheral adapta-
tion to AS. Also, even though flow-normalized indices such
as AVA are theoretically the most robust measurements of
severity, follow-up studies of unselected patients have found
prognostic value to be highest for non–flow-corrected indi-
ces such as Vmax and P (8,25,46). Placed above the other
diagnostic goals, increased clinical outcome efficacy is prob-
ably the consequence of improved technical and diagnostic-
accuracy efficacy (19). Stroke-work loss is based only on
pressure estimates, without the need of measuring flow rate.
Because the latter is the most important source of error and
variability, both in Doppler and cardiac catheterization-
derived hemodynamic calculations (10,46), SWL can be
more accurately obtained than AVA and AVR, particularly
in patients in atrial fibrillation. Also, P has shown to
correlate with symptomatic status (47), and its combination
with blood pressure has been demonstrated to powerfully
predict survival in unoperated patients (48). Stroke-work
loss mathematically incorporates both P and systolic blood
pressure, and therefore adds their individual statistical value.
The demonstration of flow-mediated changes in AVA
led some authors to postulate that stress interventions may
unmask the opening reserve available for patients to increase
Figure 4. Boxplots of indices of aortic stenosis according to the symptomatic status. Distributions are shown for peak jet velocity (A), mean transvalvular
pressure gradient (B), stroke-work loss (C), valve area (D), and valve resistance (E), for patients in Group B. Boxes represent the interquartile distance,
whereas the white line represents the median. The shaded zone represents the 95% confidence interval for the median and the whiskers represent the limits
of each distribution. Significant differences between groups are ascertained by the lack of overlap of the shaded zones. The highest difference between
asymptomatic (Asympt.) and symptomatic (Sympt.) patients is observed for stroke-work loss.
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their cardiac output (9,16,49). As valves become stiffer,
valvular reserve would decline and limit the capability of
the ventricle to increase output. Once valvular reserve
reaches a critical point, patients would develop charac-
teristic exercise symptoms. Because valve stiffness is not
directly related to baseline AVA, stress interventions are
required to assess it (10,50). However, both the present
and a previous (2) study have failed to find any additive
clinical value of stress testing in cohorts of patients with
mostly normal LV function.
Figure 5. Validation of clinical efficacy models in Group A. (A) Regression tree for calculating the probability of suffering critical aortic stenosis (AS) (prob)
according to stroke-work loss (SWL), presence or absence of symptoms, and ejection fraction (EF). (B) Cumulative probability of long-term outcome
according to SWL and symptomatic status. Patients with critical AS have been excluded. (C) Probability of early and late AS events in patients with
impaired left ventricular function (EF  0.45). p  probability of long-rank test for comparisons between categories.
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Study limitations. Stroke-work loss in the retrospective
cohort was calculated using non-simultaneous measure-
ments of P and SBP. As stated earlier, systolic blood
pressure in the echocardiography laboratory was higher than
values registered in the clinical records. However, the
impact of this small bias on calculated SWL is negligible: an
increase of SBP of 11 mm Hg (upper 95% CI of bias)
translates to only a 1% absolute decrease in SWL (23% to
22%, for average values of P and SBP in Group A).
The purpose of the study was to assess clinical perfor-
mance of AS diagnostic tests and not to analyze natural-
history predictors. Hence, the goal was to recruit a repre-
sentative sample of most subjects in whom clinical indices
are employed to guide clinical management, as recom-
mended for test evaluation designs (51). Furthermore, the
data analysis strategy was designed to minimize the number
of variables tested, and the stability of the final models was
demonstrated by resampling techniques. Using these meth-
ods, overfitting is remarkably reduced, allowing validation
populations to include groups used for model definition
(32).
Conclusions. The present study demonstrates that non–
flow-corrected indices of AS are the most clinically efficient
in terms of predicting symptomatic status and outcome.
Among them, SWL is the Doppler-echocardiographic in-
dex that best accounts for clinical severity of adult AS.
Patients showing values 25% are likely to be symptomatic
and have an adverse outcome, irrespective of symptomatic
status. Thus, SWL should be incorporated in clinical
assessment of AS and used to aid patient management in
unclear situations. Inotropic stimulation is of no prognostic
value in unselected patients.
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